Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM5 | Q9NZQ8 | 13/20 | 0.43 |
| ▸ | TRPM4 | Q8TD43 | 8/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6196313 | 0.84 | ESR1 (0.39) | ESR1ESR2HTR2CHTR2BHTR2A | |
| SCHEMBL10841342 | 0.84 | AR (0.43) | ESR1ESR2HTR2CHTR2BHTR2A | |
| SCHEMBL3258564 | 0.83 | TRPM5 (0.51) | TRPM5TRPM4 | |
| SCHEMBL6192228 | 0.82 | PNMT (0.50) | ESR1ESR2MTNR1A | |
| SCHEMBL4763545 | 0.82 | ITGB3 (0.40) | ESR1ESR2SRD5A1AHRMTNR1A | |
| SCHEMBL8238979 | 0.81 | TRPM5 (0.43) | TRPM5ESR1ESR2HTR2BMTNR1A | |
| SCHEMBL15031156 | 0.78 | PRKD3 (0.41) | ESR1ESR2HTR2BMTNR1A | |
| SCHEMBL6754201 | 0.77 | AR (0.38) | ESR1ESR2SRD5A1 | |
| SCHEMBL14822782 | 0.77 | MTNR1A (0.36) | ESR1ESR2HTR2BMTNR1A | |
| SCHEMBL6754202 | 0.77 | AR (0.38) | ESR1ESR2SRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1432701-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI IRELAND LTD (IE) | 2005-12-21 | — | — | EP | disclosed |
| CN-1564820-A | Heterocyclic compounds for use in the treatment of disorders of the urinary tract | RECORDATI CHEM PHARM (CH) | 2005-01-12 | — | — | CN | disclosed |
| EP-1432701-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 2004-06-30 | — | — | EP | disclosed |
| US-20030181446-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-09-25 | — | — | US | disclosed |
| US-20030162777-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-08-28 | — | — | US | disclosed |
| WO-2003031436-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI S.A. (CH) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162777-A1 | Novel N-acylated heterocycles | HTR1A, HTR1D, HTR1E | TRPM5 239/4885TRPM4 267/4885ESR1 1500/4885 |
| US-20030181446-A1 | Novel N-acylated heterocycles | HTR1A, HTR1E, HTR2C | TRPM5 716/4885TRPM4 832/4885ESR1 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.